Search research articles
Contact Us
Filters
Showing results (71-80 of 76) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 76 results.
International Journal of Cancer
|
January 10, 2008
17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer
Joanna M Day, Paul A Foster, Helena J Tutill, et al.
Molecular Cancer Therapeutics
|
August 30, 2008
Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography
L W Lawrence Woo, Delphine S Fischer, Christopher M Sharland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 15, 2006
Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor
Susannah J Stanway, Atul Purohit, L W Lawrence Woo, et al.
Chemical Communications (Cambridge, England)
|
April 14, 2010
Chimeric microtubule disruptors
Mathew P Leese, Fabrice Jourdan, Meriel R Kimberley, et al.
Journal of Medicinal Chemistry
|
February 12, 2008
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents
Mathew P Leese, Fabrice L Jourdan, Keira Gaukroger, et al.
Gene Regulation and Systems Biology
|
August 15, 2017
A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics
Jeffrey E Ming, Ruth E Abrams, Derek W Bartlett, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 76) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 76 results.
International Journal of Cancer
|
January 10, 2008
17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer
Joanna M Day, Paul A Foster, Helena J Tutill, et al.
Molecular Cancer Therapeutics
|
August 30, 2008
Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography
L W Lawrence Woo, Delphine S Fischer, Christopher M Sharland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 15, 2006
Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor
Susannah J Stanway, Atul Purohit, L W Lawrence Woo, et al.
Chemical Communications (Cambridge, England)
|
April 14, 2010
Chimeric microtubule disruptors
Mathew P Leese, Fabrice Jourdan, Meriel R Kimberley, et al.
Journal of Medicinal Chemistry
|
February 12, 2008
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents
Mathew P Leese, Fabrice L Jourdan, Keira Gaukroger, et al.
Gene Regulation and Systems Biology
|
August 15, 2017
A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics
Jeffrey E Ming, Ruth E Abrams, Derek W Bartlett, et al.
Page
of 8